availability of the specialties ETOPOSIDE ACCORD and HYQVIA

Hospital specialties under pressure.peterspiro / iStock / Getty Images Plus / via Getty Images

Between October 1 and 3, 2024, the National Agency for the Safety of Medicines and Health Products (ANSM) reported new disruptions or updated the availability data of several specialties marketed in France [1]distributed exclusively to the hospital.

ETOPOSIDE ACCORD: availability of the 50 mL vial postponed to mid-December

ETOPOSIDE ACCORD 20 mg/mL concentrate for infusion in 25 mL and 50 mL vials (etoposide)

Availability status according to ANSM

• for the 25 mL bottle
• for the 50 mL bottle

  • Supply voltage of the presentation in 50 mL bottle: limited distribution
  • Normal delivery of the presentation in a 50 mL bottle: mid-December 2024, instead of early November (cf. our article of September 10, 2024)

HYQVIA: Irish units as reinforcements on the French market

HYQVIA 100 mg/mL solution for subcutaneous infusion (human normal immunoglobulins)

Availability status according to ANSM

• Supply voltage
• Since January 2024, quota distribution up to usual needs (September 2023 base). The specialties of the Grifols laboratory can compensate part of the increase in additional needs observed since September 2023 up to the anticipated missing quantity.
• Exceptional and transitional provision of Hyqvia 100 mg/ml solution for infusion for subcutaneous use (30 g/300 ml) initially intended for the Irish market

Additional information from the laboratory

Newsletter from the Takeda laboratory for the attention of healthcare professionals (September 16, 2024) : the Irish units made available in France belong to batches BE16E147AA (exp. 12/2026) and BE16E213AA (exp. 12/2026). The dosage and composition of this specialty are identical to the French specialty. The CIP and UCD codes remain unchanged. Imported packaging does not have the 3 traceability labels required by French regulations. It is requested to report the necessary information in order to ensure the traceability of these batches imported by handwriting or by any other appropriate means.

Takeda laboratory newsletter to patients (September 19, 2024)